The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia and its ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Vice President Kamala Harris allies in the business community are trying to give her a boost over Donald Trump.

Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% ...

Shares of Merck & Co. Inc. MRK slipped 0.37% to $109.77 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia, for the ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission ...

Societe Generale has recently reduced Merck & Co Inc (MRK) stock to Sell rating, as announced on March 11, 2024, according to Finviz. Earlier, on January 4, 2024, TD Cowen had raised the stock from a ...

Mark Cuban, Reid Hoffman and other big names in business joined with Vice President Harris’s campaign for the launch of ...